Response to: Correspondence on ‘Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements’ by Barzel et al

We thank Belančić and colleagues1 for their thoughtful and constructive comments on our recent publication2 on the stability of ready-to-administer alglucosidase alfa infusions. We appreciate the recognition of the clinical relevance of our findings and the opportunity to address the important points raised.